Molecular Templates, Inc. provided an update on its clinical-stage programs. Eric Poma, PhD., Chief Executive and Chief Scientific Officer of MTEM, stated, ETBs are a potentially powerful therapeutic approach to selectively depleting immunosuppressive cells in oncology or eliminating self-reacting immune cells in severe immune-mediated diseases. The monotherapy activity with MT-6402 in relapsed/refractory solid tumor patients, and the clinical and ex vivo depletion of CD38+ immune cells seen with MT-0169 at well-tolerated doses underscore the potential of this platform across multiple diseases.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.12 USD | +1.82% | -0.92% | -71.05% |
06-03 | Molecular Templates, Inc. Provides Interim Update | CI |
05-15 | Earnings Flash (MTEM) MOLECULAR TEMPLATES Posts Q1 Revenue $11.1M | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-71.05% | 7.24M | |
+16.06% | 122B | |
+18.99% | 113B | |
+18.95% | 26.49B | |
-23.41% | 19.4B | |
-19.03% | 16.24B | |
-19.91% | 15.4B | |
-46.14% | 15.15B | |
+64.34% | 14.93B | |
+5.31% | 13.52B |
- Stock Market
- Equities
- MTEM Stock
- News Molecular Templates, Inc.
- Molecular Templates, Inc. Provides Interim Update